Intraoperative management of liver transplantation for familial amyloid polyneuropathy Met30: what has changed in the last 10 years?

FAMILIAL amyloid polyneuropathy (FAP) is a genetic disorder inevitably lethal without liver transplantation. This procedure has been performed for FAP since 1990 and this disease is now, by far, the most frequent metabolic indication for liver transplantation, with more than 700 patients having undergone transplantation worldwide. In the last years, results improved significantly, and FAP Met30 1-year survival rates reached 90% to 98%. Because these patients had no liver insufficiency, their livers have been used as grafts in transplantation of other patients, since October 1995, in the so-called “domino” or sequential liver transplantation.